Northern Trust’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-102,991
| Closed | -$506K | – | 4828 |
|
|
2021
Q3 | $506K | Buy |
102,991
+14,876
| +17% | +$72.2K | ﹤0.01% | 3760 |
|
|
2021
Q2 | $465K | Sell |
88,115
-946
| -1% | -$4.9K | ﹤0.01% | 3739 |
|
|
2021
Q1 | $427K | Buy |
89,061
+20,412
| +30% | +$107K | ﹤0.01% | 3860 |
|
|
2020
Q4 | $298K | Sell |
68,649
-2,544
| -4% | -$10.9K | ﹤0.01% | 3865 |
|
|
2020
Q3 | $293K | Buy |
71,193
+3,277
| +5% | +$12.7K | ﹤0.01% | 3724 |
|
|
2020
Q2 | $174K | Sell |
67,916
-224,801
| -77% | -$661K | ﹤0.01% | 3796 |
|
|
2020
Q1 | $846K | Buy |
292,717
+7,886
| +3% | +$35.3K | ﹤0.01% | 3290 |
|
|
2019
Q4 | $1.08M | Buy |
284,831
+2,285
| +0.8% | +$10.9K | ﹤0.01% | 3370 |
|
|
2019
Q3 | $1.45M | Buy |
282,546
+11,116
| +4% | +$68.6K | ﹤0.01% | 3264 |
|
|
2019
Q2 | $1.68M | Buy |
271,430
+586
| +0.2% | +$3.37K | ﹤0.01% | 3158 |
|
|
2019
Q1 | $1.93M | Sell |
270,844
-11,441
| -4% | -$103K | ﹤0.01% | 3107 |
|
|
2018
Q4 | $2.41M | Sell |
282,285
-4,431
| -2% | -$57.6K | ﹤0.01% | 2949 |
|
|
2018
Q3 | $5.74M | Buy |
286,716
+12,153
| +4% | +$285K | ﹤0.01% | 2609 |
|
|
2018
Q2 | $7.09M | Buy |
274,563
+51,508
| +23% | +$1.43M | ﹤0.01% | 2481 |
|
|
2018
Q1 | $5.33M | Buy |
223,055
+25,167
| +13% | +$793K | ﹤0.01% | 2540 |
|
|
2017
Q4 | $6.71M | Buy |
197,888
+2,289
| +1% | +$63.9K | ﹤0.01% | 2432 |
|
|
2017
Q3 | $4.14M | Buy |
195,599
+2,327
| +1% | +$42.7K | ﹤0.01% | 2741 |
|
|
2017
Q2 | $3.38M | Sell |
193,272
-10,547
| -5% | -$174K | ﹤0.01% | 2857 |
|
|
2017
Q1 | $3.57M | Buy |
203,819
+4,521
| +2% | +$77K | ﹤0.01% | 2762 |
|
|
2016
Q4 | $3.37M | Buy |
199,298
+6,945
| +4% | +$107K | ﹤0.01% | 2802 |
|
|
2016
Q3 | $3.16M | Buy |
192,353
+2,753
| +1% | +$41.8K | ﹤0.01% | 2815 |
|
|
2016
Q2 | $2.87M | Buy |
189,600
+50,086
| +36% | +$826K | ﹤0.01% | 2833 |
|
|
2016
Q1 | $2.02M | Buy |
139,514
+19,799
| +17% | +$333K | ﹤0.01% | 2974 |
|
|
2015
Q4 | $3.39M | Sell |
119,715
-620
| -0.5% | -$10.4K | ﹤0.01% | 2719 |
|
|
2015
Q3 | $2.01M | Buy |
120,335
+68,406
| +132% | +$1.56M | ﹤0.01% | 3048 |
|
|
2015
Q2 | $1.36M | Buy |
51,929
+13,357
| +35% | +$260K | ﹤0.01% | 3223 |
|
|
2015
Q1 | $674K | Buy |
38,572
+7,031
| +22% | +$120K | ﹤0.01% | 3533 |
|
|
2014
Q4 | $548K | Sell |
31,541
-358
| -1% | -$5.43K | ﹤0.01% | 3526 |
|
|
2014
Q3 | $594K | Buy |
31,899
+21,403
| +204% | +$368K | ﹤0.01% | 3531 |
|
|
2014
Q2 | $192K | Buy |
+10,496
| New | +$188K | ﹤0.01% | 3869 |
|
Northern Trust's ADMS Position: Q4 2021 in Review
Northern Trust sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 102,991 shares — an estimated $506K sold.
Northern Trust first reported a position in ADMS in Q2 2014 and held it in 30 quarters. The position peaked at $7.09M in Q2 2018. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- Northern Trust reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- Northern Trust sold 102,991 Adamas Pharmaceuticals shares in Q4 2021, an estimated $506K.
- Northern Trust first reported a position in Adamas Pharmaceuticals in Q2 2014 and held it in 30 quarters.
- Northern Trust's Adamas Pharmaceuticals position peaked at $7.09M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on Northern Trust's 13F filing for Q4 2021, filed 8 Feb 2022.